Bannerbild German Brest Group

GBG Research at ESMO Breast Cancer 2019


Data of several GBG research projects will be presented at the ESMO Breast Cancer 2019, which takes place from 2 to 4 May in Berlin, Germany.

#1080: Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: pooled analysis based on the GBG database

  • Session: Type: Proffered Paper session; Title: Best abstracts session; 3.05.2019, 16:45 - 17:00 (oral presentation)
  • First author: J. Huober J; Universitätsfrauenklinik Ulm, Germany

#15P: Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: pooled analysis of 484 patients from three prospective multicentre GBG trials

  • Session: Type: Poster display session; Title: Poster lunch; 3.05.2019, 12:15 - 13:00 (poster)
  • First author: P. Jank; Charité Universitaetsmedizin Berlin, Germany

#25P: Expression of ER, PR, HER2 and Ki-67 in the neoadjuvant GeparX trial - comparison of central immunohistochemistry (IHC) with an automated cartridge-based system for mRNA assessment

  • Session: Type: Poster display session; Title: Poster lunch; 03.05.2019; 12:15 - 13:00 (poster)
  • First author: C. Denkert; Institut für Pathologie Philipps-Universität Marburg, Germany

#122TiP: GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo

  • Session: Early breast cancer: Neoadjuvant therapy; 3.05.2019; 12:15 – 13:00 (poster, trial in progress)
  • First author: S. Loibl; GBG, Neu-Isenburg, Germany


  • 11.10.2018 BIG newsletter no 9 is out

    We’re delighted to announce that the BIG newsletter BIG Research in Focus, Issue 9 is out and has been published on BIG’s website.

    Mehr ...
  • 27.09.2018 Paper of the month: models for pCR

    Paper of the month: models for pCR

    A statistical research study that aimed to develop an empirical model for predicting the magnitude of the treatment effects on survival endpoints based on the treatment effects on pathological complete response (pCR) has been published in the Contemporary Clinical Trials.

    Mehr ...
  • 11.09.2018 BCC-Breast Cancer Conference 2019 in Vienna

    BCC-Breast Cancer Conference 2019 in Vienna

    The 16th St. Gallen International Breast Cancer Conference 2019 in Vienna is less than seven months away.

    Mehr ...
  • 31.08.2018 Paper of the month: Endocrine Therapy in HEGR2 neg mBC

    A review that summarized the available data on endocrine therapy for premenopausal women with HER2-negative hormone receptor-positive metastatic breast cancer (MBC) has been published in the Oncologist.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd